| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| SCHALL & ASHENFARB | 10,000 | 5,000 | 5,000 | |
| EISNERAMPER LLP | 10,571 | 5,285 | 5,286 |
| Description of Property | Date Acquired | Cost or Other Basis | Prior Years' Depreciation | Computation Method | Rate / Life (# of years) |
Current Year's Depreciation Expense | Net Investment Income | Adjusted Net Income | Cost of Goods Sold Not Included |
|---|
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| 101,500 SHS IMMUNOVANT PHARM | 4,688,285 | 4,688,285 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| RTW INNOVATION ONSHORE FUND | FMV | 1,059,339 | 1,059,339 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| PREPAID TAXES | 0 | 11,000 | 11,000 |
| Description | Amount |
|---|---|
| UNREALIZED LOSS | 570,357 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| OTHER FEES | 374 | 374 | ||
| INVESTMENT EXPENSES | 270 | 270 | ||
| OTHER EXPENSES THROUGH K-1: | ||||
| OTHER EXPENSES | 2,593 | 2,593 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| Income Through K-1 RTW Innovation | 274 | 274 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| CONSULTING FEES | 78,644 | 78,644 |